NCT04889404Completed
LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)
LYNPARZA Tablets 100 mg, 150mg General Drug Use-results Study in Patients on Maintenance Treatment After Platinum-based Chemotherapy for BRCA Mutated Curatively Unresectable Pancreas Cancer
Source: ClinicalTrials.gov · Last updated 14 Jan 2026
Brief summary (registry, in English)
To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual post-marketing use of LYNPAZA.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 130 (actual)
- First submitted
- 12 May 2021
- Start date
- 22 May 2021
- Primary completion date
- 6 Feb 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Pancreatic cancer, Childhood cancers
- NCT number
- NCT04889404
What you commit to
- Study type: Observational
- Participants enrolled: 130
- From 22 May 2021 to the primary completion date, 6 Feb 2025
- 31 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who have no treatment history with LYNPARZA
Who the study is looking for
- Patients who receive LYNPARZA for the first time for the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated curatively unresectable pancreas cancer after the approval date of partial change application for the additional indication (25/Dec./2020).
Sex: All · Does not accept healthy volunteers
Sites (31)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.